MOTOVSKA, Z., Jiří JARKOVSKÝ, A. KOVARIK, J. MROZEK, Ota HLINOMAZ, J. PRECEK, M. HROMADKA, A. ZOHOR, Petr KALA, P. TOMASOV, P. CERVINKA, J. MATEJKA, Klára BENEŠOVÁ and S. DRABKOVA. Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis. In ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands. 2023. ISSN 0195-668X. Available from: https://dx.doi.org/10.1093/eurheartj/ehad655.1493.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparison of ticagrelor and prasugrel just before PCI in NSTE acute coronary syndromes, LIKE-ACCOAST analysis
Authors MOTOVSKA, Z. (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), A. KOVARIK (203 Czech Republic), J. MROZEK (203 Czech Republic), Ota HLINOMAZ (203 Czech Republic), J. PRECEK (203 Czech Republic), M. HROMADKA (203 Czech Republic), A. ZOHOR (203 Czech Republic), Petr KALA (203 Czech Republic, belonging to the institution), P. TOMASOV (203 Czech Republic), P. CERVINKA (203 Czech Republic), J. MATEJKA (203 Czech Republic), Klára BENEŠOVÁ (203 Czech Republic) and S. DRABKOVA (203 Czech Republic).
Edition ESC Congress 2023 25-28 August 2023 Amsterdam, Netherlands, 2023.
Other information
Original language English
Type of outcome Conference abstract
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 39.300 in 2022
RIV identification code RIV/00216224:14110/23:00133231
Organization unit Faculty of Medicine
ISSN 0195-668X
Doi http://dx.doi.org/10.1093/eurheartj/ehad655.1493
Keywords (in Czech) ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes
Keywords in English ticagrelor; NSTE ACS; prasugrel; acute coronary syndromes
Tags FN KV, RIV, rivok, user, článek v časopise
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 19/2/2024 13:41.
Abstract
Recommendations for the preference of prasugrel over ticagrelor just before PCI in NSTE ACS are based on limited and controversial evidence. Furthermore, prasugrel can’t be used in patients after a stroke/TIA, and the risk of bleeding in older and low-weight patients annuls its benefit. Purpose We aimed to add to the current evidence comparing the benefit of prasugrel and ticagrelor just before PCI (without pretreatment) in NSTE ACS patients.
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 13/6/2024 18:36